南华早报，1月16日

China’s experimental ALS drug SNUG01 has unexpected results for patient, may be useful for Parkinson’s, Alzheimer’s, stroke victims

中国实验性药物SNUG01在患者身上表现出意外效果，或可助力帕金森、阿尔茨海默和中风患者

记者 Dannie Peng

报道节选：

Now a potential new drug being tested by a group of Chinese scientists and clinicians may offer a glimmer of hope, with promising results after it was used on a severely affected patient for six months.

近日，一组中国科学家和临床医生正在测试的潜在新药可能为人们带来一线希望。一名病情严重的患者使用新药六个月后，取得了令人鼓舞的结果。

Huang Xusheng, a professor at the neurology department of the First Medical Centre of China’s PLA General Hospital, said it was all “very encouraging”.

中国解放军总医院第一医学中心神经内科黄旭升教授表示，这一切都是“非常令人鼓舞的”。

“The placebo effect usually lasts about two months,” Fan said. In this case, however, they found that the patient’s condition was still under control after six months of treatment, so he is confident any placebo effect could be ruled out.

“通常安慰剂效应只持续两个月左右，”樊东升教授表示。然而，在这个案例中，他们发现患者接受六个月治疗后，病情仍然得到有效控制，因此他有信心可以排除安慰剂效应。

SNUG01: A New Ray of Hope in the Battle against ALS

SNUG01：ALS战斗中的新曙光

记者 Aqsa Younas Rana

报道节选：

Compared to the current FDA-approved genetic therapy Tofersen, which targets a gene mutation present in only 2% of ALS sufferers, SNUG01 holds the potential to cast a wider net in its application.

与目前仅适用于ALS患者中2%基因突变的FDA批准基因疗法Tofersen相比，SNUG01的应用范围更为广泛。

The development of SNUG01 resonates with China’s initiative to boost local biotech innovation, providing a glimmer of optimism for ALS patients worldwide.

SNUG01的研发与中国本土生物技术创新的推动相契合，为全球ALS患者带来一丝乐观的曙光.